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Abstract
Background: Accumulation mode particles (AMP) are formed from engine combustion and make up the inhalable
vapour cloud of ambient particulate matter pollution. Their small size facilitates dispersal and subsequent exposure
far from their original source, as well as the ability to penetrate alveolar spaces and capillary walls of the lung when
inhaled. A significant immuno-stimulatory component of AMP is lipopolysaccharide (LPS), a product of Gram negative
bacteria breakdown. As LPS is implicated in the onset and exacerbation of asthma, the presence or absence of LPS in
ambient particulate matter (PM) may explain the onset of asthmatic exacerbations to PM exposure.
This study aimed to delineate the effects of LPS and AMP on airway inflammation, and potential contribution to airways
disease by measuring airway inflammatory responses induced via activation of the LPS cellular receptor, Toll-like receptor
4 (TLR-4).
Methods: The effects of nebulized AMP, LPS and AMP administered with LPS on lung function, cellular inflammatory
infiltrate and cytokine responses were compared between wildtype mice and mice not expressing TLR-4.
Results: The presence of LPS administered with AMP appeared to drive elevated airway resistance and sensitivity via
TLR-4. Augmented TLR4 driven eosinophilia and greater TNF-α responses observed in AMP-LPS treated mice independent
of TLR-4 expression, suggests activation of allergic responses by TLR4 and non-TLR4 pathways larger than those induced
by LPS administered alone. Treatment with AMP induced macrophage recruitment independent of TLR-4 expression.
Conclusions: These findings suggest AMP-LPS as a stronger stimulus for allergic inflammation in the airways then
LPS alone.
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Background
Exposure to ambient air pollution is an adverse health
risk to respiratory health, particularly in the young, eld-
erly and those with co-morbidities such as heart disease
[1, 2]. In the young, epidemiological and toxicological
research studies consistently demonstrate air pollution
as a major risk factor in the onset of asthma [3, 4]. This
is well illustrated by rising rates of asthma observed in
developing countries such as China where expanding
industrialization correlates with raised airborne pollution
[1]. While in the elderly, long term exposure to particu-
late matter (PM) has been implicated in developing
COPD [1, 2, 5, 6]. Not surprisingly, hospital admission
rates for breathing difficulties have been shown to rise
during times of raised ambient air pollution concentra-
tions [3]. Despite the risks of air pollution exposure be-
ing well accepted, the precise mechanisms leading to the
onset of these chronic airway diseases are poorly under-
stood [6–9].
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Ambient air pollution, comprised in part by AMP, is a
complex mixture of organic compounds, different sized
particles and chemicals [10]. The US EPA refers to the
inhalable solid phase of ambient air pollution as PM cate-
gorized as; coarse (≤ 10 μm), fine (≤ 2.5 μm) and ultrafine
(≤ 0.1 μm) [11]. Accumulation mode particles (AMP)
straddle the ultrafine particulate (UFP) and fine categories
making up the inhalable vapour cloud of PM [12]. AMP’s
are largely sourced from engine combustion. Due to their
small size these are subject to wind and other climatic
conditions which enable dispersal and exposure far from
their source of origin [13]. As AMP are small enough to
penetrate alveolar spaces and capillary walls, exposure to
this particulate size fraction has been shown to result in
respiratory disease and exacerbation, with exposure also
linked to cardiovascular disease [12, 13].
To date, the majority of air pollution toxicology stud-
ies have explored the role of whole ambient mixtures
and individual chemical components on respiratory
health [7–9]. Due to the number of stimuli within ambi-
ent air, identifying the causes and/or interactions re-
sponsible for the onset of disease is difficult, as these
can trigger a variety of host defence mechanisms when
inhaled [14–16]. Oxidative particulates and/or reactive
oxygen species generated by particulate phagocytosis
have been shown to drive proinflammatory pathways
which can cause long-term lung damage and airway dis-
ease [17–19]. There is also evidence to suggest Toll like
receptor (TLR)-2 and TLR-4 activation in these PM
driven inflammatory processes as part of an inflamma-
some driven response [20–23].
The TLR family are well described pattern recognition
receptors that detect characteristic microbial motifs to
signal the presence of invading microbial organisms [24].
TLR function forms part of the innate immune system
and induce pro-inflammatory cytokine release. These
signals alert and activate surrounding tissues and the
adaptive immune system [24]. Bacteria are detected by
TLR-2 and TLR-4 which recognise components of Gram
positive and Gram negative bacterial cell walls known as
lipotoeic acid (LTA) and lipopolysaccharide (LPS, also
known as endotoxin) respectively [24]. Recognition of ei-
ther LTA and LPS by TLR’s induces a cascading inflam-
matory response which can be severe as in the case of
sepsis when bacteria are found in blood [25].
Both LTA and LPS form a significant immuno-
stimulatory component of ambient air. This has been
shown by reduced inflammatory responses in cell cul-
tures treated with ambient PM preparations mixed with
polymixin B, a compound binding the Lipid A moiety of
LPS [26]. While exposure to LPS has been shown to ex-
acerbate asthma there is conflicting evidence to suggest
it also modulates allergic airway responses [27, 28]. The
role of TLR-2 and TLR-4 in responses to ambient PM
has been further elucidated in alveolar macrophages, a
key phagocyte in the lung [29]. However, the overall ef-
fects of LPS and PM (including AMP) deposited in the
lower airways and the impact of this on lung function
and immune modulation has not been fully investigated.
In this study we aimed to delineate the individual and
combined effects of LPS and AMP on airway inflamma-
tion and potential contribution to airway disease. Due to
the well documented inflammatory effects of LPS, we hy-
pothesized that airway inflammation induced by exposure
to AMP would be augmented when AMP was co-
administrated with LPS. Using a mouse model, the inhaled
effects of nebulised AMP, LPS and AMP administered to-
gether with LPS on lung function, inflammatory cell infil-
trate and cytokine responses in bronchoalveolar lavage
and lung parenchymal tissue. To determine the role of
TLR-4 in AMP and LPS induced airway inflammation, re-
sults were compared between wildtype mice and mice not
expressing TLR-4. As PM size fractions contain a mixture
of compounds which includes attached LPS [10, 30], an
inert fluorescent bead model was used in order to clearly
assess the impact of AMP delivered with a known amount
of LPS attached.
Methods
Animals
We used commercially available fluorescent polystyrene
beads as a model for inert AMP (Fluoresbrite™ polychro-
matic red microspheres, Polysciences Inc., Pennsylvania,
USA; herein referred to as AMP) exposure as has been
used previously [31]. In this study, mice with a mutated
non-functional TLR-4 expression (C3H/HeJ, referred to
as TLR4−/−) and mice of the same strain expressing
TLR-4 (C3H/HeN, referred to as wildtype, WT) were
used in order to assess changes in respiratory mechanics
and lung inflammation in response to nebulized treat-
ments of AMP, LPS and a mixed AMP-LPS preparation.
TLR4−/− mice have been previously characterized with
dysfunctional TLR-4 expression due to a spontaneous
proline to histidine point mutation in the TLR-4 signal-
ing sequence [32]. This mouse model is commonly used
as a negative control for TLR-4 expression in studies in-
vestigating TLR-4 responses [33, 34]. Mice were used at
7–9 weeks of age (Animal Resource Centre, Murdoch,
Western Australia) and housed in a controlled environ-
ment with a 12 h light to dark cycle with unrestricted
access to food and water. All experiments presented
were approved by the Telethon Kids Institute’s Animal
Ethics Committee (approval reference #128) and carried
out in accordance with the recommendations of the
Australian code for the care and use of animals for
scientific purposes 8th edition (2013).
Ten mice of each strain were grouped to receive the
following nebulized treatments: LPS alone (50 μg/ml,
Fonceca et al. Respiratory Research  (2018) 19:15 Page 2 of 10
Salmonella typhimurium, Sigma-Aldrich, St. Louis, Mis-
souri, USA); 0.5 μm polystyrene beads alone (50 μg/ml,
equating to approximately 7.26 × 1010 particles/ml of
AMP; both AMP and LPS (AMP-LPS, 50 μg/mL); or
double-distilled water (control). Double distilled water
and AMP nebulization preparations contained < 0.015
EU/ml (detection limit) using the Limulus amebocyte
lysate (LAL) assay (Sigma-Aldrich, Missouri, USA).
Double distilled water induced less airway resistance to
methacholine at doses above 3 mg/ml during challenge
compared to endotoxin free 0.9% saline, confirming
suitability of this as a control for these studies (see
Additional file 1: Figure S1) [35]. To best represent short
term exposure inducing an inflammatory response, mice
were exposed to their allocated treatment at constant
flow of 3 ml/min for 30 min at the same time for six
consecutive days. Nebulized aerosols were delivered to
animals via an UltraNeb™ nebulizer (DeVilbiss, Somerset,
Pennsylvania, USA), as described previously [36]. Ac-
cording to DeVilbiss, nebulized droplet size distribution
generated ranges from 0.5-3 μm [37]. As a solution of
0.5 μm polychromatic spheres were used, the overall
nebulization range was deemed to fit the accumulation
mode particle size range (0.1–2.5 μm) for the purposes
of this study.
Lung function measurements
Lung function was assessed using a modification of the
low frequency, forced oscillation technique (LFOT).
Mice were initially anaesthetized with an intraperitoneal
injection of a solution containing xylazine (2 mg/ml,
Troy Laboratories, NSW, Australia) and ketamine
(40 mg/ml, Troy Laboratories, NSW, Australia) at a dose
of 0.01 mg/g. Mice were then tracheotomized and a
10 mm section of polyethylene tubing (1.27 mm OD,
0.86 mm ID) inserted into the trachea. Mice were venti-
lated at 450 breaths/min with a tidal volume of 8 ml/kg
and a positive end expiratory pressure (PEEP) of 2 cm
H2O using a computer-controlled ventilator (flexiVent,
SCIREQ Inc., Montreal, Canada). This system was used
for ventilation and measurement of respiratory mechan-
ics as previously described [38, 39].
Before commencing lung function measurements,
mouse lung volume history was standardized using 5
deep inflations to total lung capacity. Respiratory imped-
ance (Zrs) was measured using an oscillatory signal con-
taining 19 frequencies ranging from 0.25 to 19.625 Hz
during pauses in ventilation. Zrs was partitioned into
components representing the mechanical properties of
the airways and lung tissue parenchyma using a four
parameter model with constant phase tissue impedance
[38, 39]. Partitioning of Zrs in this way allows calculation
of parameters representing airway resistance, tissue
damping and tissue elastance [40, 41].
Methacholine challenge
Following measurement of baseline Zrs, mice were
exposed to a saline aerosol for 90s (Ultraneb™ 99, Devil-
biss, Somerset, Pennsylvania, USA). Five measurements
of Zrs were then obtained, averaged and used as the
control measurements for MCh challenge. The aerosol
procedure was repeated with half log incremental doses
of MCh from 0.1 to 30 mg/ml. Measurements of Zrs
were recorded every minute for 5 min after each MCh
aerosol and the maximum response calculated. From
these, data dose response curves for airway resistance
(Raw) were constructed. Sensitivity to MCh was deter-
mined by calculating the MCh dose required to produce
a 200% increase in Raw in response to the saline chal-
lenge at 30 mg/ml using interpolation [41]. Maximum
responses in Raw and airway sensitivity were used to
compare lung function responses between groups.
Inflammatory cell counts
Five additional animals per group were anaesthetised
and tracheotomised for bronchoalveolar lavage (BAL)
used for inflammatory cell infiltrate and inflammatory
cytokines analysis as previously described [40]. Briefly,
BAL fluid was collected by slowly infusing and with-
drawing a 1 ml aliquot of 0.9% saline from the lung
three times. The resulting fluid was centrifuged at
2000 rpm for 4 min. Supernatant was collected and
stored at −80 °C for later analysis. The cell pellet was re-
suspended in saline and a portion stained with trypan
blue to determine viability and total cell count (TCC).
The remaining portion was centrifuged onto slides and
stained with Leishman’s (Sigma-Aldrich, St Louis, Mis-
souri, USA) to obtain differential cell counts.
Inflammatory cytokine responses
Bronchoalveolar lavage (BAL)
Analysis of BAL for the presence of secreted pro-
inflammatory cytokines known to be secreted in response
to LPS and PM [42]. Interleukin (IL)-6, Interferon (IFN)-γ,
and Tumor necrosis factor (TNF)-α was completed using
a cytokine bead array assay (BD Biosciences California,
USA) as per manufacturers’ instructions, with a detection
range of 20-5000 pg/ml for all cytokines within the array.
These measurements were completed in BAL from five
mice of each mouse strain for each treatment using an
optimized sample dilution factor.
Lung parenchyma
Soluble protein was extracted from a single mouse lung
lobe to gain a measure of subepithelial pro-inflammatory
responses indicative of airway remodelling and developing
chronic airway inflammation. For this reason expression
of immune-regulatory, IL-10 and pro-fibrotic cytokine,
IL-13, were examined using ELISA (R&D Systems,
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Abdington, UK; detection ranges: IL-10, 31.2-2000 pg/ml
and IL-13, 62.5-4000 pg/ml) using optimised sample dilu-
tion factors. Specifically, IL-10 was chosen as it is secreted
in response to LPS and is thought to protect the lung
against lung injury by reducing the production of proin-
flammatory cytokines, chemokines and transcription fac-
tors implicated in airway remodelling. Whereas IL-13 is
known to be involved in subepithelial fibrosis related to
the onset of asthma and COPD. Data was calculated and
normalized to 100 μg of total soluble protein as measured
using the Pierce BCA assay (Thermo-Pierce, Rockford,
USA) for comparative purposes.
Statistical analysis
SPSS Levene’s test was used to test for equal variance
across all the groups of data compared. Following verifi-
cation, an independent t-test was then used to determine
statistically significant differences between (a) controls
and treatment groups and (b) single treatments between
WT and TLR4−/− mice. Due to differences in baseline
lung function (see results Table 1), responses to MCh
were expressed as a percentage of baseline with graphs
are shown as mean ± SEM. Due to the range of data,
cytokine responses are presented as box and whisper
plots depicting interquartile range and 2.5 and 97.5
percentiles with medians. A minimum of 4 biological
replicates and p values < 0.05 considered significantly
different were used for all data sets.
Results
Lung function
Baseline lung function responses were recorded for each
animal prior to saline and methacholine (MCh) challenge
(Table 1). Baseline airway resistance (Raw) values were el-
evated in all TLR4−/− mice compared to wildtype (WT)
mice of the same treatment (PM p = 0.04, LPS p = 0.03,
PM-LPS p = 0.035), including control mice (p = 0.035); in-
dicating this mouse strain had more sensitive airways
overall. However, baseline Raw did not vary considerably
between mice of the same strain treated with AMP, LPS
or AMP-LPS nebulisations (Table 1).
At 30 mg/ml MCh, Raw was significantly augmented
in WT mice treated with nebulized LPS or AMP-LPS
compared to control mice (p = 0.04 and 0.03
respectively, Fig. 1a). Sensitivity to MCh as determined
by interpolation, was significantly less in WT mice
treated with LPS (p = 0.008) and AMP-LPS (p = 0.017)
compared to controls. This was not observed in LPS and
AMP-LPS treated TLR4−/− mice, indicating more sensi-
tive airways in response to LPS and AMP-LPS treat-
ments in the presence of TLR-4 (Fig. 1b). Responses for
all other doses of MCh used for challenge can be found
in Additional file 2: Figure S2.
Cellular responses measured in bronchoalveolar lavage
Bronchoalveolar lavage (BAL) inflammatory total cell
counts were larger in WT mice treated with AMP, LPS (p
< 0.001) and AMP-LPS (p < 0.001) compared to WT con-
trol mice. Total cell counts in WT mice treated with LPS
(p < 0.001) and AMP-LPS (p < 0.001) were greater than
similarly treated TLR4−/− mice (Fig. 2a). Neutrophils
were the predominant cell type in LPS and AMP-LPS
treated WT mice compared to control and AMP treated
mice (p < 0.001) (Fig. 2b). In contrast, neutrophils were
barely detectable in TLR4 −/− mice irrespective of expos-
ure. Macrophages were the dominant cell type in mice
treated with AMP irrespective of strain (p = 0.01 for both
strains) and in TLR4−/− mice treated with LPS (p = 0.007)
and AMP-LPS (p = 0.04) compared to respective controls
(Fig. 2c). Eosinophil numbers were greater in WT mice
treated with LPS (p = 0.006) and AMP-LPS (p < 0.001); for
which numbers were larger in AMP-LPS treated mice (p
= 0.024) compared to those treated with LPS. Lymphocyte
and epithelial cell numbers were not significantly different
between controls and any of the treatments given for
either strain. Other cytokine responses measured using
the commercial kit can be found in Additional file 3: Fig-
ure S3.
Inflammatory cytokine responses
Bronchoalveolar lavage
Significantly increased levels of IFN-γ, IL-6 and TNF-α
were observed in wildtype and TLR4−/− mice treated
with LPS (Wildtype: IFN-γ p = 0.02; IL-6 p = 0.002;
TNF-α p = 0.001, TLR4−/−: IFN-γ p < 0.001; IL-6 p <
0.001; TNF-α p < 0.001) and AMP- LPS (Wildtype: IFN-
γ p < 0.001, IL-6 p < 0.001, TNF-α p = 0.001, TLR4−/−:
IFN-γ p < 0.001; IL-6 p < 0.001; TNF-α p < 0.001), with
Table 1 Baseline lung function for mice studies completed in control and treated wildtype (WT) and TLR4 (TLR4 −/−) mutant mice.
Baseline lung function measurements taken before methacholine challenge were not significantly different between treatments in
WT and TLR4−/− mice. Greater Raw values were measured for all TLR4−/− mice compared to WT mice of the same treatment,
indicating that overall, this mouse strain had more sensitive airways
Treatment Control AMP LPS AMP-LPS
Mouse strain WT TLR4−/− WT TLR4−/− WT TLR4−/− WT TLR4−/−
Raw (hPa.s.ml−1) 0.35 0.45* 0.34 0.46* 0.34 0.40* 0.34 0.45*
(0.01) (0.02) (0.01) (0.02) (0.01) (0.03) (0.01) (0.02)
*p < 0.05 between WT and TLR4−/−,()indicates SD
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greater amount of cytokine in wildtype mice for these
treatments (LPS p = 0.028 and APM-LPS p < 0.001)
(Fig. 3). Only AMP-LPS treated TLR4−/− mice had sig-
nificantly more TNF-α compared to LPS treated TLR4
−/− mice (p = 0.032). The amounts of these cytokines
were not significantly different in AMP treated mice
compared to control mice for both strains.
Lung parenchyma
Soluble protein was extracted from one whole mouse
lung lobe and analysed by ELISA for IL-10 and IL-13
expression showed no differences in these cytokines for
any treatment in WT or TLR4−/− mice compared to
controls (p > 0.05 for all; Fig. 4). Similarly, there were
no differences observed between WT and TLR4−/−
mice for any of the individual inhaled treatments
administered (p > 0.05).
Discussion
The results of this study clearly demonstrate that the in-
flammatory effects of inhaled particulate matter are heavily
influenced by the presence of LPS. Airway resistance and
sensitivity were shown to correlate inflammatory cytokine
responses to inhaled LPS and AMP-LPS measured in
bronchoavleolar lavage. While these responses were more
pronounced when signalled by TLR-4, inflammation was
also observed in TLR-4 knock-out mice indicating other
LPS recognition pathways. A larger TNF-α response ob-
served in TLR-4 knockout mice treated with AMP-LPS
Fig. 1 Airway resistance (a) and sensitivity to methacholine at
30 mg/ml (b) for wildtype (WT) and mice not expressing TLR4 (TLR4
−/−) for each treatment. Airway resistance (Raw) values for the
largest methacholine challenge (MCh, 30 mg/ml) are presented as a
percentage of the initial saline challenge given to each animal given
prior to commencing MCh challenges (a). Raw was augmented in
WT mice treated with nebulized LPS and AMP-LPS only. Airway
sensitivity was calculated by interpolating the amount of MCh
needed to cause a doubling of baseline responses (b). WT mice
treated with LPS and AMP-LPS required significantly less MCh than
that needed for control mice, indicating more sensitive airways due
to LPS and AMP-LPS treatments in the presence to TLR-4 (*p < 0.05
compared to controls). No significant differences were observed in
airway resistance or sensitivity between treatments of LPS or AMP-LPS
within each mice strain (p > 0.05)
Fig. 2 Bronchoalveolar lavage (BAL) total (a) and differential cell
counts (b, c) for wildtype (WT) and mice not expressing TLR4 (TLR4
−/−) for each treatment. Elevated total cell counts in BAL were observed
in WT mice treated with AMP, LPS and AMP-LPS compared to WT
control mice. Cell counts in WT mice treated with LPS and AMP-LPS
were also greater than similarly treated TLR4−/− mice. Neutrophils
were the predominant cell type in LPS and AMP-LPS treated WT mice.
Macrophages dominated counts in AMP treated WT and TLR4−/−
mice, as well as LPS and AMP-LPS treated TLR4−/− mice compared to
respective controls. Greater eosinophil numbers were observed in WT
mice treated with LPS and AMP-LPS; for which numbers were greater
in AMP-LPS treated mice. Lymphocyte and epithelial cell numbers
were not significantly different between controls and any of the treat-
ments given for either strain (*p < 0.05 between treatment and control;
# = p < 0.05 between strains for the same treatment; α = p < 0.05
between treatment compared to all other treatments for the
same strain)
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compared to LPS alone, suggest alternate recognition or a
divergent signalling pathway for this treatment combin-
ation. As there were no changes observed in IL-10 or IL-
13 expression measured in lung parenchymal tissue, this
suggests the inhaled preparations used in this study did
not have an effect on airway tissue remodelling. Interest-
ingly, elevated macrophage numbers observed in mice
treated with inhaled latex beads alone, used as the model
for AMP in this study, was not mimicked by increased in-
flammatory cytokine levels or augmented airway responses
when compared to control non-treated mice.
Raised ambient PM levels are shown to be directly
correlated to asthma admissions in health care centres,
with long term exposure linked to the onset of lung
cancer and COPD [2]. In this study, we did not find any
significant change in lung function resulting from AMP
exposure. However, augmented airway resistance and
airway sensitivity responses to methacholine were ob-
served in wildtype mice exposed to LPS and AMP-LPS.
As LPS is found ubiquitously in the environment our
data suggests LPS attached to inhalable AMP induces
changes in lung function rather than AMP alone. As
AMP exposure is linked to the onset of chronic diseases
such as COPD, asthma and even cardiovascular disease
a longer study period may be more suitable. This would
allow tracking of slow onset of symptoms which underlie
these diseases in response to ongoing long-term expos-
ure to inhaled AMP.
Neutrophilic inflammation present in wildtype mice
treated with LPS and AMP-LPS compared to TLR4−/−
mice indicates this response was driven by the presence
of TLR-4 driven by the presence of LPS. In the absence
of TLR-4, cellular inflammation to LPS and AMP-LPS
was dominated by the presence of macrophages. AMP
alone also induced increased macrophage infiltration
compared to control mice, however this was observed ir-
respective of TLR-4 expression. Elevated macrophage
numbers suggests either strengthened recruitment to the
lung to clear inhaled particles, or impaired clearance, a
hallmark of alveolar macrophages overloaded with
phagocytosed particles [43–48]. On the other hand, lar-
ger neutrophil numbers in response to particle inhal-
ation have been shown to correlate the onset of cancer
tumors, an observation which dissipates when particle
deposition shifts from the alveolar space to lung intersti-
tium [49]. Airway deposition of AMP particles was not
characterised in this study; however, these observations
clearly demonstrate a greater number of macrophages
with unchanged neutrophil numbers compared to non-
treated control mice. Therefore, these findings suggest
an interstitial lung deposition of AMP with induced in-
flammatory responses independent of TLR-4 expression
for the first time. Interestingly, eosinophil numbers were
significantly higher in wildtype mice treated with AMP-
Fig. 3 Cytokine responses measured in bronchoalveolar lavage
collected from treated wildtype (WT) (□) and mice not expressing
TLR4 (TLR4−/−) (■). Significantly elevated IFN-γ, IL-6 and TNF-α was
observed in WT and TLR4−/− mice treated with LPS and AMP-LPS,
with these results being greater in WT mice. Only AMP-LPS treated
TLR4−/− mice had significantly more TNF-α compared to LPS treated
TLR4−/− mice. The amount of these cytokines was not significantly
different in AMP treated mice compared to control mice for both
strains (* indicates p < 0.05 compared to controls, α = p < 0.05 single
treatment compared to all other treatments for the same strain)
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LPS compared to LPS. Indeed distinct TLR-4 driven
cellular compartments have been shown to activate
neutrophilic and eosinophilic responses in response to
different allergens [50], which may explain the larger eo-
sinophil responses observed in wildtype mice treated
with AMP-LPS compared to LPS alone. As eosinophilia
is closely associated with the onset of asthma and allergy
[50, 51], further investigation of this finding may eluci-
date the cellular mechanisms underlying allergic airway
disease caused by exposure to particulates.
Of those treated wildtype mice, LPS or AMP-LPS
induced the largest inflammatory cytokine responses
measured in BAL. Augmented responses to LPS and
AMP-LPS were also observed in TLR4−/− mice, illustrat-
ing proinflammatory signalling mechanisms other than
TLR-4 activated by LPS. Furthermore, TNF-α levels were
significantly greater in BAL of AMP-LPS treated TLR4−/−
mice compared to LPS treated mice, suggesting this
combination was signalled by yet another mechanism. As
we found evidence for LPS being attached to AMP, ele-
vated TNF- α levels may have been induced by alternate
receptors for LPS (such as scavenger receptors), or endocy-
tosed resulting in recognition by intracellular pattern rec-
ognition receptors for LPS; including nucleotide-binding
oligomerization domain (NOD) receptors contained in cel-
lular inflammasomes [51]. Indeed, Shi et al. have shown
binding of LPS by caspase 11 is critical for activation of this
intracellular process [51]. Augmented TNF-α responses
have been shown in the presence of eosinophilia [52, 53].
Thereby the combination of elevated non-TLR4 driven
TNF-α and TLR-4 driven eosinophilia observed in AMP-
LPS treated mice suggest AMP-LPS is a stronger stimulus
for allergic inflammation in the airways than LPS alone.
Despite a larger number of macrophages observed in AMP
treated mice, these did not display inflammatory cytokine
responses that were significantly different to those
measured in non-treated control mice.
Interestingly, IL-10 or IL-13 measured in the lung par-
enchyma remained unchanged in response to all inhaled
treatments for wildtype and TLR4−/− mice. This is sur-
prising given the long-standing relationships between
AMP exposure and airway disease development charac-
terised by airway remodelling co-ordinated by these cy-
tokines [54, 55]. Within the context of this study, this
novel finding suggests TLR-4 driven inflammatory
responses activated by LPS recognition appear to be pre-
dominantly secreted (BAL). However, as long term-low
grade inflammation activity can go undetected in sube-
pithelial tissues for long periods [55], a larger study
period may elucidate mechanisms pertinent to slow
onset airway disease attributable to AMP exposure such
as COPD and related cardiovascular disease [56]. Im-
portantly, IL-13 responses are associated with allergen
associated airway disease such as asthma [57]. Elevated
TNF-α responses measured in BAL to LPS suggests
modulation of this response by type-2 inflammatory cy-
tokines such as IL-4 or IL-5. Although closely affiliated
with IL-4, IL-13 responses observed in lung parenchyma
did not correlate LPS induced TNF-α responses in BAL
[58]. Therefore, findings from a longer study period
which include analysis of IL-4 or IL-5 may be valuable to
our overall understanding of immune-modulated airway
disease in response to allergic stimuli carried in inhaled
air such as LPS, which has remained elusive to date [9].
Conclusions
In conclusion, we have shown the presence of LPS in
AMP preparations has an influential impact on induced
airway and inflammatory BAL responses in the lung
which are augmented by the presence of TLR-4. Import-
antly, dominant macrophage responses observed in BAL
from AMP treated mice over all other treatments, sug-
gest interstitial lung deposition, triggered regardless of
TLR-4 expression for the first time. Despite this,
Fig. 4 Cytokines measured in lung parenchymal tissue from wildtype (WT) (□) and mice not expressing TLR4 (TLR4−/−) (■) treated with AMP, LPS
and AMP-LPS. There were no observed differences in IL-10 and IL-13 protein expression measured from whole mouse lung lobe analysed by
ELISA for between mouse strains for any treatment or for any treatment compared to control non-treated mice (p > 0.05). Results were normalised
to 100 μg of total soluble protein for comparative purposes (n =minimum of 4 for each group)
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inflammatory cytokine responses were not observed in
the lung parenchymal tissues in response to any treat-
ment, suggesting a longer study period may be needed
to observe pro-fibrotic changes that underlie airway dis-
ease caused by long-term AMP inhalation. Interestingly,
when AMP was attached to LPS larger TNF-α responses
independent of TLR-4 expression were observed in BAL
suggesting activation of allergic responses by non-TLR4
pathways. If augmented by TLR-4 driven eosinophilia as
observed in AMP-LPS treated mice, these findings
suggest AMP-LPS as a stronger stimulus for allergic
inflammation in the airways over LPS alone. Taken to-
gether, these results demonstrate divergent response
pathways in the lung to AMP and LPS, with larger
allergy affects observed in AMP-LPS which have not
been shown before. Therefore, these findings contribute
novel information to the field investigating the onset of
allergic and non-allergic airway disease, such as asthma
and COPD, as a result of PM exposure and warrants
further investigation.
Additional files
Additional file 1: Figure S1. Airway resistance in TLR4−/− mice
treated with double distilled water (ddH2O) and saline. Saline responses
were significantly greater for methacholine challenges larger than 3 mg/
ml (* p < 0.05). (TIFF 356 kb)
Additional file 2: Figure S2. Airway resistance in wildtype (WT) and
TLR4−/− mice for all treatment groups across for all methacholine
challenges used. Raw was significantly greater in WT mice treated with
LPS and AMP-LPS compared to control mice at 30 mg/ml MCh
(*p < 0.05). (TIFF 1196 kb)
Additional file 3: Figure S3. Additional cytokines measured in
bronchoalveolar lavage (BAL) and lung parenchyma. MCP-1 was measured
in BAL using cytokine bead array assay (20-5000 pg/ml detection range)
and IL-8 in lung parenchyma using ELISA (15.6-1000 pg/ml detection range)
using optimised sample dilution factors. No significant difference with
treatment was observed for these cytokines. (TIFF 558 kb)
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